Published in Biotech Business Week, May 5th, 2003
Asmanex (mometasone furoate), an orally inhaled corticosteroid, will be combined with Foradil (formoterol fumarate), a selective, long-acting beta2-agonist, in a single inhalation device. Terms of the agreement are not being disclosed.
"Combining the therapeutic benefits of Asmanex and Foradil in a single device could significantly enhance the ability of doctors to control the symptoms of asthma and COPD," said Thomas Ebeling, CEO of Novartis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.